Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

NCT05376579 · clinicaltrials.gov ↗

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Active Secondary Progressive Multiple Sclerosis

Interventions

OTHER: siponimod

Sponsor

Novartis Pharmaceuticals